A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

NCT06226090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: TG103 7.5 mg
DRUG: Placebo 7.5 mg
DRUG: TG103 15 mg
DRUG: Placebo 15 mg
DRUG: TG103 22.5 mg
DRUG: Placebo 22.5 mg

Sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.